About AFYREN
AFYREN is a company based in Paris (France) founded in 2012 by Jeremy Pessiot, Regis Nouaille, and Nicolas Sordet. AFYREN has raised $25.59 million across 6 funding rounds from investors including Bpifrance, Valquest Capital Management and Sofinnova Partners. AFYREN offers products and services including Biobased Acetic Acid, Biobased Propionic Acid, and Biobased Butyric Acid. AFYREN operates in a competitive market with competitors including Spore Biotechnologies, Biopsin, Mesosil, Celsis and Source Molecular, among others.
- Headquarter Paris, France
- Founders Jeremy Pessiot, Regis Nouaille, Nicolas Sordet
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Afyren Sas
-
Annual Revenue
$2.97 M (USD)-15.3as on Dec 31, 2024
-
Net Profit
-$10.13 M (USD)-1.75as on Dec 31, 2024
-
EBITDA
-$6.13 M (USD)-4.54as on Dec 31, 2024
-
Total Equity Funding
$25.59 M (USD)
in 6 rounds
-
Latest Funding Round
$8.25 M (USD), Post-IPO
Feb 25, 2026
-
Investors
Bpifrance
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AFYREN
AFYREN is a publicly listed company on the EURONEXT with ticker symbol ALAFY in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AFYREN
AFYREN offers a comprehensive portfolio of products and services, including Biobased Acetic Acid, Biobased Propionic Acid, and Biobased Butyric Acid.
Fermentation-derived acid replacing petroleum-based versions in industries.
Biobased acid for use in feed and food preservation applications.
Sustainable acid applied in flavors and functional fluids sectors.
People of AFYREN
Unlock access to complete
Unlock access to complete
Funding Insights of AFYREN
AFYREN has successfully raised a total of $25.59M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $8.25 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AFYREN
AFYREN has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, Valquest Capital Management and Sofinnova Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
Financial support is provided for SMEs and startups in Auvergne.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for AFYREN
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AFYREN
Investment portfolio details for AFYREN
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AFYREN
Detailed financials for AFYREN
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Afyren Comparisons
Peer comparison for AFYREN
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AFYREN
AFYREN operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spore Biotechnologies, Biopsin, Mesosil, Celsis and Source Molecular, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Microbial detection technology is developed for life science industries.
|
|
| Locked | Locked | Locked |
Real-time microbial detection system is developed for product testing.
|
|
| Locked | Locked | Locked |
Antimicrobial materials are developed for infection prevention in medical devices.
|
|
| Locked | Locked | Locked |
Rapid microbial screening systems are manufactured for quality control testing.
|
|
| Locked | Locked | Locked |
Technology for microbial source tracking is provided by Source Molecular.
|
Detailed competitors of AFYREN
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Afyren
Complete news archive for AFYREN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AFYREN
AFYREN was founded in 2012 and raised its 1st funding round 3 years after it was founded.
AFYREN is headquartered in Paris, France.
Nicolas Sordet is the current CEO of AFYREN. They have also founded this company.
AFYREN is a funded company, having raised a total of $25.59M across 6 funding rounds to date.
Annual revenue of AFYREN is $2.97M as on Dec 31, 2024.
AFYREN was founded in 2012 and is based in Paris, France. Operations focus on the biotechnology sector, where analytical services are delivered for microbiology, chemistry, and bioprocesses industries. The Afynerie technology is utilized to convert non-food biomass wastes into high-value biomolecules. Services encompass measurements of methane or biogas production from organic substrate degradation by anaerobic microorganisms, alongside physicochemical characterization of organic substrates.
AFYREN's top competitors include Spore Biotechnologies, NCIMB and Biopsin.
AFYREN offers Biobased Acetic Acid, Biobased Propionic Acid, and Biobased Butyric Acid.
Yes, AFYREN is publicly traded on EURONEXT under the ticker symbol ALAFY.
AFYREN has 6 investors. Key investors include Bpifrance, Valquest Capital Management, Sofinnova Partners, JEREMIE Auvergne, and Kemin.
The ticker symbol of AFYREN is ALAFY on EURONEXT.